Archives of Clinical Infectious Diseases

Published by: Kowsar

Study of Serologic Response Rate to Haemophilus influenzae Type B After Administration of the Third Dose of Pentavalent Vaccine in Children Aged 12 Months in Karaj City in 2016

Reza Arjmand 1 , Mehri Gholami 2 , Fariba Shirvani 3 , * , Omid Safari 1 , Mostafa Qorbani 4 and Mohammad Javad Gharavi 5
Authors Information
1 Department of Pediatric, Shahid Bahonar Hospital, Alborz University of Medical Sciences, Karaj, Iran
2 Alborz University of Medical Sciences, Karaj, Iran
3 Pediatric Infectious Diseases Research Center (PIRC), Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Community Medicine, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
5 Department of Parasitology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: October 2018, 13 (5); e59344
  • Published Online: August 20, 2018
  • Article Type: Research Article
  • Received: August 2, 2017
  • Revised: March 9, 2018
  • Accepted: April 8, 2018
  • DOI: 10.5812/archcid.59344

To Cite: Arjmand R, Gholami M, Shirvani F, Safari O , Qorbani M, et al. Study of Serologic Response Rate to Haemophilus influenzae Type B After Administration of the Third Dose of Pentavalent Vaccine in Children Aged 12 Months in Karaj City in 2016, Arch Clin Infect Dis. 2018 ; 13(5):e59344. doi: 10.5812/archcid.59344.

Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Peltola H. Worldwide Haemophilus influenzae type B disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13(2):302-17. [PubMed: 10756001]. [PubMed Central: PMC100154].
  • 2. Feikin DR, Nelson CB, Watt JP, Mohsni E, Wenger JD, Levine OS. Rapid assessment tool for Haemophilus influenzae type B disease in developing countries. Emerg Infect Dis. 2004;10(7):1270-6. doi: 10.3201/eid1007.030737. [PubMed: 15324548]. [PubMed Central: PMC3323330].
  • 3. Wenger JD, DiFabio JL, Landaverde JM, Levine OS, Gaafar T. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four "newly adopting" countries. Vaccine. 1999;18(7-8):736-42.
  • 4. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Haemophilus influenzae type B in children younger than 5 years: global estimates. Lancet. 2009;374(9693):903-11. doi: 10.1016/s0140-6736(09)61203-4.
  • 5. World Health Organization. WHO position paper on Haemophilus influenzae type B conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record. Wkly Epidemiol Rec. 2006;81(47):445-52. [PubMed: 17124755].
  • 6. World Health Organization. WHO Factsheet. 2016. Available from:
  • 7. Ansari N, Porrostami K, Farzaneh F, Zibai M. [Serologic investigation of Hflu B in children under six years old (Khoramabad- I.R. Iran)]. Sci Res J Alborz Med Univ. 2015;4(2):84-90. Persian.
  • 8. Jahromi AS, Rahmanian K. Natural immunity to hemophilus influenza type B in children, south of Iran: need for vaccination. Pak J Biol Sci. 2012;15(3):160-3. [PubMed: 22866548].
  • 9. [No Authors Listed]. Schedule and guideline of immunization, approved by National Immunization Technical Advisry Group. I.R. Iran. 2015.
  • 10. Booy R, Taylor SA, Dobson SR, Isaacs D, Sleight G, Aitken S, et al. Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule. Arch Disease Childhood. 1992;67:475–478.
  • 11. Kelly DF, Moxon ER, Yu LM, Pollard AJ. Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type B immunization of infants in the United Kingdom. Clin Vaccine Immunol. 2009;16(2):246-52. doi: 10.1128/CVI.00023-08. [PubMed: 18784340]. [PubMed Central: PMC2643546].
  • 12. Peltola H. Spectrum and burden of severe Haemophilus influenzae type B diseases in Asia. Bull World Health Organ. 1999;77(11):878-87. [PubMed: 10612883]. [PubMed Central: PMC2557760].
  • 13. Shetty S, Cohen AL, Edmond K, Ojo L, Loo J, O'Loughlin R, et al. A systematic review and critical evaluation of invasive Haemophilus influenzae type B disease burden studies in Asia from the last decade: lessons learned for invasive bacterial disease surveillance. Pediatr Infect Dis J. 2010;29(7):653-61. doi: 10.1097/INF.0b013e3181d3ce19. [PubMed: 20168264].
  • 14. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type B conjugate vaccine use and effectiveness. Lancet Infect Dis. 2008;8(7):435-43. doi: 10.1016/S1473-3099(08)70152-X. [PubMed: 18582836].
  • 15. Hutter J, Pasetti MF, Levine MM, Tapia MD, Sow SO, Sanogo D. Naturally acquired and conjugate vaccine-induced antibody to haemophilus influenzae type B (hib) polysaccharide in malian children: serological assessment of the hib immunization program in Mali. Am J Trop Med Hyg. 2012;86(6):1026-31. doi: 10.4269/ajtmh.2012.11-0807.
  • 16. Frayha HH, Shaheen H, Ganelin RS, Kattan HA, Tufenkeji HT, Krotzer S, et al. Clinical and serologic responses of saudi children to hemophilus influenzae type B capsular polysaccharide diphtheria toxoid conjugate vaccine. Ann Saudi Med. 1993;13(3):215-21. doi: 10.5144/0256-4947.1993.215.
  • 17. Guimaraes T, Cereda RF, Bianchin PJ, Nagao AT, Sampaio MC, Mendonca JS. Antibody response to Haemophilus influenzae type B tetanus conjugate vaccine with two doses given at 3 and 5 months of age. Int J Infect Dis. 2002;6(2):113-7. [PubMed: 12121598].
  • 18. Arvas A, Gur E, Bahar H, Torun MM, Demirci M, Aslan M, et al. Haemophilus influenzae type B antibodies in vaccinated and non-vaccinated children. Pediatr Int. 2008;50(4):469-73. doi: 10.1111/j.1442-200X.2008.02591.x. [PubMed: 19143969].
  • 19. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting. The Journal of Pediatrics. 2003;143(6):163-87. doi: 10.1067/s0022-3476(03)00576-6.
  • 20. Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type B (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol. 2007;14(10):1328-33. doi: 10.1128/CVI.00191-07. [PubMed: 17699835]. [PubMed Central: PMC2168123].
  • 21. Eskola J, Kayhty H, Takala AK, Peltola H, Ronnberg PR, Kela E, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type B disease. N Engl J Med. 1990;323(20):1381-7. doi: 10.1056/NEJM199011153232004. [PubMed: 2233904].
  • 22. Low N, Redmond SM, Rutjes AWS, Martínez-González NA, Egger M, di Nisio M, et al. Comparing Haemophilus influenzae type B conjugate vaccine schedules: a systematic review and meta-analysis of vaccine trials. Pediatr Infect Dis J. 2013;32(11):1245-56.

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments